Zevra Therapeutics Inc (ZVRA)
4.65
-0.02
(-0.43%)
USD |
NASDAQ |
May 31, 16:00
4.65
0.00 (0.00%)
After-Hours: 20:00
Zevra Therapeutics Gross Profit Margin (Quarterly): 50.28% for March 31, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 50.28% |
| December 31, 2023 | 84.88% |
| September 30, 2023 | 95.03% |
| June 30, 2023 | 92.01% |
| March 31, 2023 | 96.06% |
| December 31, 2022 | 98.91% |
| September 30, 2022 | 95.09% |
| June 30, 2022 | 96.08% |
| March 31, 2022 | 99.80% |
| December 31, 2021 | 97.71% |
| Date | Value |
|---|---|
| September 30, 2021 | |
| June 30, 2021 | 91.66% |
| March 31, 2021 | 91.75% |
| December 31, 2020 | |
| September 30, 2020 | |
| June 30, 2020 | 90.71% |
| March 31, 2020 | 68.26% |
| December 31, 2019 | -41.35% |
| September 30, 2019 | 91.28% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
-41.35%
Minimum
Dec 2019
99.80%
Maximum
Mar 2022
81.13%
Average
91.88%
Median
Gross Profit Margin (Quarterly) Benchmarks
| Perspective Therapeutics Inc | -- |
| Dare Bioscience Inc | -- |
| OptiNose Inc | 91.73% |
| Kodiak Sciences Inc | -- |
| INmune Bio Inc | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -80.02% |
| Return on Assets | -37.72% |
| Return on Invested Capital | -53.77% |
| Profit Margin (Quarterly) | -485.3% |
| Operating Margin (Quarterly) | -598.1% |
| Return on Net Operating Assets | -99.92% |